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Robert J. Langenhorst,a Steven Lawson,a Apisit Kittawornrat,b Jeffrey J. Zimmerman,b Zhi Sun,a Yanhua Li,a
Jane Christopher-Hennings,a Eric A. Nelson,a and Ying Fanga
Department of Veterinary and Biomedical Science, South Dakota State University, Brookings, South Dakota, USA,a and Department of Veterinary Diagnostic and
Production Animal Medicine, Iowa State University, Ames, Iowa, USAb
For effective disease surveillance, rapid and sensitive assays are needed to detect antibodies developed in response to porcine
reproductive and respiratory syndrome virus (PRRSV) infection. In this study, we developed a multiplexed fluorescent micro-
sphere immunoassay (FMIA) for detection of PRRSV-specific antibodies in oral fluid and serum samples. Recombinant nucleo-
capsid protein (N) and nonstructural protein 7 (nsp7) from both PRRSV genotypes (type I and type II) were used as antigens and
covalently coupled to Luminex fluorescent microspheres. Based on an evaluation of 488 oral fluid samples with known serosta-
tus, the oral fluid-based FMIAs achieved>92% sensitivity and 91% specificity. For serum samples (n 1,639), the FMIAs
reached>98% sensitivity and 95% specificity. The assay was further employed to investigate the kinetics of the antibody re-
sponse in infected pigs. In oral fluid, the N protein was more sensitive for the detection of early infection (7 and 14 days postin-
fection), but nsp7 detected a higher level and longer duration of antibody response (28 days postinfection). In serum, the anti-
bodies specific to nsp7 and N proteins were detected as early as 7 days postinfection, and the responses lasted more than 202
days. This study provides a framework fromwhich a more robust assay could be developed to profile the immune response to
multiple PRRSV antigens in a single test. The development of oral fluid-based diagnostic tests will change the way we survey dis-
eases in swine herds and improve our ability to cheaply and efficiently track PRRSV infections in both populations and individ-
ual animals.
Porcine reproductive and respiratory syndrome (PRRS) is themost economically devastating disease in the swine industry.
One of the key approaches to achieving PRRS elimination is to
identify PRRS virus (PRRSV)-infected pigs so that such pigs can
be quarantined, isolated, or removed from herds to block or re-
duce the transmission of infection to susceptible animals. Serum is
a standard antemortem sample that is routinely collected for di-
agnostic evaluation to determine whether pigs have been exposed
to PRRSV. However, blood collection is a labor-intensive proce-
dure and may cause stress to the animal. Previous studies evalu-
ated the use of oral fluid sampling as an efficient, cost-effective
approach to PRRSV surveillance in swine populations (11, 12).
Oral fluid is a complex mixture of saliva and gingival crevicular
fluid. Gingival crevicular fluid is an oral mucosal transudate de-
rived from the passive transport of serum components through
the oral mucosa into the gingival crevices of the mouth. It more
closely resembles serum than salivary gland secretions. The use of
oral fluid samples as an inexpensive, safe, noninvasive alternative
to blood in determining acute infection and prevalence of immu-
nity has become well established for various human pathogens,
such as human immunodeficiency virus (HIV), hepatitis A and B
viruses, and rubella virus (2, 3, 5, 10). Oral fluid has been used in
epidemiological studies of HIV infection in developing countries
and potentially has a role in epidemiological studies of other hu-
man infectious agents (5, 9). The presence of PRRSV in oral fluids
was first reported in 1997, when the virus was isolated frombuccal
swabs collected from experimentally inoculated young pigs at 7,
14, 21, 28, 35, and 42 days postinoculation (13). A recent study by
Prickett et al. (11) reported that PRRSV in oral fluid was detected
by real-time quantitative reverse transcription-PCR (qRT-PCR) for
approximately4weekspostinoculation.Certain levelsof anti-PRRSV
antibody were detected in oral fluid samples by use of the commer-
cially available IDEXXHerdChekPRRS enzyme-linked immunosor-
bent assay (ELISA) and indirect immunofluorescent-antibody (IFA)
tests. These reports suggested that porcineoral fluid samples couldbe
used for diagnostic monitoring of PRRSV infection.
The use of traditional immunoassays to detect host antibodies
in oral fluid is less sensitive than using sera due to the lower con-
centration of host antibodies present in oral fluid. In this study, we
used a fluorescent microsphere immunoassay (FMIA) to detect
anti-PRRSV antibodies in oral fluid specimens. The FMIA uses
multiple fluorescent microspheres (up to 100 color-coded bead
sets), and each bead set is conjugated to different antigens or an-
tibodies as the solid phase for the detection of antibodies or anti-
gens in biological samples. An advantage of this technology is that
FMIA allows uniformdetection ofmultiple antigens or antibodies
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simultaneously within a small volume of a single sample. There-
fore, the assay is less labor-intensive and requires smaller amounts
of samples.
Traditional antibody detection assays, such as the IDEXX
HerdChek PRRS ELISA, are based on the PRRSV nucleocapsid
(N) protein as the antigen.Our previous study showed that certain
nonstructural proteins, nsp1, nsp2, and nsp7, are also highly im-
munogenic (1). Serum antibodies specific to these proteins can be
detected as early as 14 days postinfection (dpi) and last more than
202 dpi. Recently, we developed an nsp7-based ELISA for detect-
ing PRRSV antibodies in serum samples (1). In this study, we
adapted the N protein- and nsp7-based ELISAs into a multiplex
FMIA format for the diagnosis of PRRSV infection in oral fluid.
For comparison, FMIAs using serum samples were also devel-
oped. These new FMIAs for the detection of antibody against
PRRSV represent the first step in the development of a broad
range of multiplex assays for swine disease diagnostics. Future
expansion of these assays would allow for the rapid detection of
various antigens and antibodies associated with major swine
pathogens in a single sample.
MATERIALS AND METHODS
Viruses and cells.MARC-145 cells were cultured in minimal Eagle’s me-
dium (MEM; Gibco BRL Life Technologies) with 10% fetal bovine serum
(FBS) and antibiotics (100 units/ml penicillin and 20 g/ml streptomy-
cin). Cells were maintained at 37°C in a humidified 5% CO2 incubator.
PRRSV strains SD01-08 (type I) andVR2332 (type II) were propagated on
MARC-145 cells by using a previously described method (6).
Expression of recombinant nsp7 and N proteins. DNA fragments
corresponding to NA-nsp7 andNA-N from type II PRRSV strain VR2332
and to EU-nsp7 and EU-N from type I PRRSV strain SD01-08 were am-
plified by RT-PCR and cloned into a pET protein expression vector (No-
vagen). Primers used for amplification of theNA-nsp7 or EU-nsp7 region
were described previously (1). For recombinant N protein expression,
primers VR2332-NF (5=-CGCGGATCCATGCCAAATAACAACGGC)
and VR2332-NR (5=-CACCTCGAGTCATGCTGAGGGTGATG) were
used for RT-PCR amplification from VR2332, and primers SD01-08-NF
(5=-CGCGGATCCATGGCCGGTAAAAATCAGAG) and SD01-08-NR
(5=-CACCTCGAGTTAATTTGCACCCTGACTG) were used for RT-
PCR amplification from SD01-08. Recombinant proteins were expressed
as His-tagged fusion proteins and purified as we described previously (1,
4). Purified fusion proteins were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) to determine their pu-
rity. Western blotting was performed to confirm the specificity of the
proteins, using an anti-His antibody (Novagen, Madison, WI).
Oralfluidandserumsamples. (i) Samples for establishing standards
and diagnostic test validation. Four sets of oral fluid and serum samples
were used. They were obtained from experimentally infected pigs follow-
ing sample collection procedures described elsewhere (7, 11, 12). The first
set of samples (sample set A) was paired oral fluid and serum samples
from individual boars (7). A total of 70 boars ranging from 5months to 4
years in age were inoculated intramuscularly with 2 ml (1  105 50%
tissue culture infective doses [TCID50]/ml) of RespPRRS modified live
vaccine (group 1; n  24), type I (strain D09-012131) PRRSV (group 2;
n  22), or type II (strain MN-184; GenBank accession no. AY656992)
PRRSV (group 3; n  24). Paired oral fluid and serum samples were
collected from all 70 boars at7,6,5,4,3,2,1, 0, 7, 14, and
21 days postinfection (dpi). The second set of samples (sample set B) was
oral fluid and serum samples collected from 30 pigs. Pigs were 6 weeks old
at the time of inoculation and were divided into three groups (n  10).
Group 1 pigs were inoculated intramuscularly with type I PRRSV strain
SD01-08 (2 ml at 1  106 TCID50/ml), group 2 pigs were inoculated
intramuscularly with type II PRRSV strain VR2332 (2 ml at 1  105
TCID50/ml), and group 3 pigs were mock infected. Serum and oral fluids
were collected once a week at regular intervals for 49 days. Serum samples
were collected from individual pigs, and oral fluid samples were collected
from each pen (n 10). The third set of samples (sample set C)was serum
samples obtained from 109 pigs experimentally infected with VR2332.
Sera were collected at 7-day intervals for the first 2 weeks and then at
14-day intervals for up to 202 dpi. In addition, a panel of serum samples
(sample set D) was obtained from 32 pigs that were experimentally inoc-
ulated with one of four different type I PRRSV isolates: SD01-07, SD01-
08, SD02-11, or SD03-15 (1). The sera were collected at 7-day intervals for
up to 85 days postinoculation.
(ii) Samples for time course study of antibody response. A panel of
oral fluid samples (sample set E) was obtained from 1,100 pigs that were
vaccinated with the RespPRRS modified live vaccine. Oral fluid was col-
lected at1, 10, 14, 21, 28, 35, 42, 49, and 56 days postvaccination. Sam-
ples for each day postvaccination were collected from individual pens and
pooled. To study the kinetics of the antibody response in serum, serum
samples from sample set C were used.
(iii) Samples for application of FMIA to field samples. A total of 772
field serum samples (sample set F) were obtained from the South Dakota
Animal Disease Diagnostic Laboratory. Positive test samples (n  383)
were used only for submitted cases having a herd history of PRRSV-
positive status and for which the IDEXX ELISA and IFA results of the
entire case were shown to be positive. This set of samples represents a wide
range of sample value/positive value (S/P) ratios for IDEXXELISA results,
including 143 samples with S/P ratios of1.9, 200 samples with S/P ratios
of 1.0 to 1.8, and 40 samples with S/P ratios of 0.4 to 1.0. The negative test
samples (n  389) were from cases having a herd history of PRRSV-
negative status and for which the IDEXX ELISA and IFA results were
verified to be negative for the entire case.
Establishment of test standards.ForELISAandFMIA standards, sep-
arate lots of internal quality control oral fluid or serum samples, generated
from sample sets A toD, were established. The values for ELISA standards
were established as “high positive” (optical density [OD] of1.9 to 2.1),
“lowpositive” (ODof0.6 to 0.7), or negative (ODof0.2). The optimal
dilution of recombinant protein was determined such that the control
sample generated anOD at the established standard. For FMIA standards,
the high-positive serological standard was established for mean fluores-
cence intensities (MFI) of 25,000 to 30,000, and the low-positive serolog-
ical standard was established for MFI of 10,000 to 15,000. Negative-
control standards were collected from uninfected animals and used to
establish a baseline (MFI of 300 to 1,000) which had at least a 10 times
lower MFI for optimum discrimination between positive and negative
samples.
AntibodydetectionELISAs. IDEXXELISA (HerdChekPRRSX3)was
performed following the manufacturer’s instructions (IDEXX Laborato-
ries). This assay is routinely conducted at the South Dakota Animal Dis-
ease Research and Diagnostic Laboratory, under strict quality control
guidelines. Results were quantified by reading plates at 650 nm with an
EL800 microplate reader (BioTek Instruments Inc., Winooski, VT) con-
trolled byXChek Software (IDEXXLaboratories). The rawplate datawere
copied to an Excel spreadsheet to calculate the S/P ratios, using the fol-
lowing formula: S/P  (OD of sample  OD of buffer)/(OD of positive
control OD of buffer).
Covalent coupling of recombinant nsp7 and N proteins to fluores-
centmicrospheres. Fluorescentmicrosphere couplingwas performed us-
ing a previously described method (8). Briefly, 3.125 106 microspheres
werewashed twicewith 250l activation buffer (0.1MNaH2PO4, pH6.2)
and sonicated for 60 s after each wash. Microspheres were activated for
20 min at room temperature in 500 l activation buffer containing
2.5 mg N-hydroxysulfosuccinimide (sulfo-NHS) and 2.5 mg N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide (EDC) (Pierce Chemical,
Rockford, IL). Activated microspheres were washed twice with
phosphate-buffered saline (PBS) and sonicated after each wash. Coupling
was initiated by the addition of 250g of each of the four purified recom-
binant proteins (EU-nsp7, NA-nsp7, EU-N, and NA-N) to a final volume
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of 500 l PBS, and samples were incubated in the dark for 3 h at room
temperature. Coupled microspheres were washed once with 1 ml of PBS
plus 0.05% NaN3 plus 1.0% bovine serum albumin (PBS-NB) and
blocked with an additional 1 ml of PBS-NB for 30 min to reduce nonspe-
cific binding. Microspheres were then washed twice and resuspended in
PBS-NB to a final concentration of 2.0  106 antigen-coupled micro-
spheres/ml.
The amount of recombinant protein coupled to a microsphere was
optimized by performing multiple coupling reactions with various con-
centrations of antigen (starting with 500 g). The amount of antigen was
titrated against a fixed number of microspheres (3.125  106) and then
tested to generate a maximal signal-to-noise ratio of MFI using standard
oral fluid or serum.
To determine the coupling efficiency, 2.5 103 antigen-coupled mi-
crospheres were added to each column well of a 96-well microtiter filter
plate that was prewetted with 20 l of PBS-NB. A solution of PBS-NB
containing 1.0 mg/ml of each monoclonal antibody (MAb) (anti-EU-
nsp7, anti-NA-nsp7, anti-EU nucleocapsid, and anti-NA nucleocapsid)
was serially titrated with 10-fold dilutions. Fifty microliters of serially
diluted antigen-specific MAb was added to corresponding wells contain-
ing coupled microspheres and allowed to incubate at room temperature
for 1 h on a plate shaker. After washing of the microspheres with PBST
(PBS plus 0.05% Tween 20) three times, 50 l of goat anti-mouse IgG
conjugated to streptavidin–R-phycoerythrin (SAPE) (10 g/ml in PBS-
NB; Invitrogen) was added to the antigen-antibody-microsphere mixture
and incubated for 30 min at room temperature. Microspheres were
washed with PBST three times and resuspended in 125 l of PBST. The
microspheres were then transferred to a 96-well polystyrene optical plate.
Uncoupled microspheres were included as a negative control. Micro-
spheres were analyzed through a dual-laser Bio-Rad Bio-Plex 200 instru-
ment. Data were analyzed with Bio-Plex Manager software (version 6.0).
The mean fluorescence intensity for 100 microspheres was recorded at
each titration point, and a logarithmic regression curve was generated.
Relative coupling efficiencies for each antigen-coated microsphere were
determined by analyzing the MFI at each dilution point and position
under the linear portion of the curve.
FMIA. A 96-well hydrophilic membrane filter plate was blocked for 2
minwith 150l of PBS-NB and then aspirated via a vacuummanifold and
wetted with an additional 20 l of PBS-NB buffer. Fifty microliters of
serum or oral fluid sample (diluted 1:50 or 1:3, respectively, in PBS-NB)
was added to duplicate filter plate wells, along with 50 l of PBS-NB
containing 2.5  103 (each type) antigen-coupled microspheres (1.0 
104 microspheres in total per well for the 4-plex assay). Since the micro-
spheres and reporter moiety are light sensitive, all incubations were per-
formed in the dark by sealing the plate with foil. For the serum FMIA, the
plate was incubated at room temperature for 1 h on a plate shaker rotating
at 600 rpm. For the oral fluid FMIA, the plate was incubated at 4°C over-
night. The plate was washed three times with 150 l of PBST. For the
serum FMIA, 50l of biotinylated IgG (1:5,000 dilution in PBS-NB; Jack-
son ImmunoResearch Laboratories) was added to the filter plate and in-
cubated at room temperature for 1 h. The oral fluid FMIA was treated the
same as the serum FMIA, except that biotinylated IgA and IgM (1:5,000
dilution in PBS-NB; Bethyl Laboratories) were added along with biotin-
FIG 1 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of recom-
binant PRRSVprotein preparations, followed byCoomassie blue staining. The
left lane shows the protein molecular mass standard; the remaining lanes rep-
resent EU nsp7, NA nsp7, EUN, and NAN protein preparations, as indicated.
NA, North American genotype (type II); EU, European genotype (type I).
FIG 2 Fluorescent microsphere immunoassay development. (A) Reactivity of
antigen-coupled beads with internal control oral fluid or serum samples. (B)
Coupling efficiency of antigen-coated beads determined using antigen-specific
MAb. Note that an antigen-specific MAb was detected at 1 ng/ml in each
FMIA. MFI, mean fluorescence intensity.
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ylated IgG as secondary antibodies. After incubation with the secondary
antibodies, 50 l of SAPE (2.5 g/ml in PBS-NB) was added to each well
and incubated for 30 min at room temperature with shaking. The super-
natant was aspirated, and the plate was washed three times with PBST.
Finally, themicrosphereswere resuspended in 125l of PBSTperwell and
transferred to a clear 96-well polystyreneoptical plate.Coupledmicrospheres
were analyzed through a dual-laser Bio-Rad Bio-Plex 200 instrument. The
MFI for 100microspheres corresponding to each individual bead analytewas
recorded for each well. All reportedMFImeasurements were normalized via
F  F0, where F0 was the background signal determined from the fluores-
cencemeasurement of a test sample in uncoated beads and Fwas theMFI for
a serological test sample in antigen-coated beads.
Assay validation. (i) Cutoff determination and diagnostic sensi-
tivity and specificity. To accurately assess the diagnostic sensitivity
and specificity of the assays, the assays were validated using samples
from two distinct animal populations. The negative-testing (nonin-
fected) validation population was composed of 385 negative oral fluid
and 368 negative serum samples. The positive-testing (infected) vali-
dation population was composed of 103 positive oral fluid and 892
positive serum samples. Receiver operating characteristic (ROC) anal-
ysis was conducted for each assay to determine assay cutoffs and diag-
nostic performance, using MedCalc, version 10.4.0.0 (MedCalc Soft-
ware, Mariakerke, Belgium).
(ii) Measurement of repeatability. The repeatability of each FMIA
was assessed by running the same lot of internal quality control standards
for oral fluid or serum multiple times on different plates. For both nsp7
andnucleocapsid assays, the intra-assay repeatability was calculated for 36
replicates on a single plate and then repeated over a 3-day period for
interassay repeatability assessment. Each assay was run in a 4-plex format,
and mean fluorescence intensity values are expressed as means, standard
FIG3 Optimization of the amount of oral fluid (A) or serum (B) for fluorescentmicrosphere immunoassay. The amount of internal standard samplewas titrated
2-fold against a fixed number of antigen-microsphere complexes and then tested in FMIA to generate a maximal signal-to-noise ratio for MFI.
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deviations, and percent coefficients of variation (%CV) for repeatedmea-
surements. %CV was calculated using a method described earlier (1, 4).
Statistical analysis. The comparison of means and determination of
%CV between groups were performed using GraphPad InStat, version
3.06 (GraphPad Software, San Diego, CA). In addition, Pearson’s corre-
lation coefficient was calculated using the same software for the determi-
nation of relative coupling efficiencies and for the comparison of single-
plex versus multiplex assays.
RESULTS
Expression of recombinant nsp7 and N proteins. To develop an
FMIA multiplex test, we initially expressed recombinant proteins
NA-nsp7 and NA-N from type II PRRSV strain VR2332 and EU-
nsp7 and EU-N from type I PRRSV strain SD01-08 as His-tagged
fusion proteins in Escherichia coli. Both EU-nsp7 and NA-nsp7
were expressed at high levels, and they were purified in soluble
FIG 4 Determination of diagnostic sensitivity (Sens) and specificity (Spec) by ROC analysis of oral fluid-based FMIA (A) and serum-based FMIA (B). Diagnostic
sensitivity and specificity were calculated using samples from a known PRRSV-infected swine population (103 oral fluid and 892 serum samples) and a known
PRRSV-negative swine population (385 oral fluid and 368 serum samples). ROC analysis was performed using MedCalc, version 10.4.0.0 (MedCalc Software, Mari-
akerke, Belgium). In each panel, the dot plot on the left represents the negative population, and the dot plot on the right side represents the positive population. A
horizontal line between the positive and negative populations represents the cutoff value that gives the optimal diagnostic sensitivity and specificity.
Langenhorst et al.
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forms. In contrast, recombinant EU-N and NA-N formed inclu-
sion bodies, and a protein refolding step was performed. The pu-
rity of the recombinant proteins was evaluated using SDS-PAGE
followed by Coomassie blue staining. As shown in Fig. 1, all of the
His-tagged recombinant proteinsmigrated according to their pre-
dicted sizes. Recombinant nsp7 proteins showed bands of around
30 kDa, with95% purity. The protein concentration was deter-
mined to be approximately 1.2 mg/ml. Recombinant N proteins
showed bands of 17 kDa, with90% purity and a concentration
of 1.8 mg/ml. The identity of each protein was further confirmed
byWestern blot analysis with anti-His antibody (data not shown).
Fluorescentmicrosphere immunoassay development. (i) Es-
tablishment of control standards. Two sets of internal control
standards were established using the sera or oral fluid collected
from experimental animals (sample sets A to D). Both serum and
oral fluid standards were established as “high positive,” “low pos-
itive,” or “negative.” The high-positive standard generates an OD
of 1.9 to 2.1 in ELISA and anMFI of 25,000 to 29,000 in FMIA. The
low-positive standard generates an OD of 0.6 to 0.7 in ELISA and
an MFI of 12,000 to 15,000 in FMIA. The negative standard gen-
erates an OD of 0.2 in ELISA and an MFI of 800 to 1,200 in
FMIA (Fig. 2A).
(ii) Test optimization. To determine the optimal concentra-
tions for antigen coupling, a series of couplings were performed
using various concentrations of antigen andwere analyzed against
control standards in order to determine the optimum amount of
antigen per microsphere. Four sets of beads, each containing
3.125  106 beads, were incubated with various concentrations
(500 g, 250 g, and 100 g) of purified EU-nsp7, NA-nsp7,
EU-N, or NA-N recombinant protein. Based on the highest
signal-to-noise ratio for detection of PRRSV-specific antibodies in
standard oral fluid or serum, we determined that 250 g per cou-
pling reaction (80 g protein/1 106 microspheres) was the op-
timal concentration for the coupling of EU-nsp7, NA-nsp7,
EU-N, andNA-Nproteins. The coupling efficiency of the antigen-
coated beads was determined using an antigen-specific monoclo-
nal antibody at log10 dilutions. As shown in Fig. 2B, relative cou-
pling efficiency curves were generated, and an average correlation
coefficient (R2) of 0.998was calculatedwithin the linear portion of
the curve for all regression analytes.
The optimal serumand oral fluid dilutionswere determined by
diluting serum and oral fluid samples in a log2 titration. Figure 3
shows concentration-dependentMFI signals. For oral fluid FMIA
(Fig. 3A), it was determined that a 1:3 dilution of oral fluid sam-
ples gave an optimal signal-to-noise ratio, while for serum FMIA
(Fig. 3B), a 1:50 dilution of serum samples gave an optimal signal-
to-noise ratio.
(iii) Cutoff determination, diagnostic sensitivity, and diag-
nostic specificity.MedCalc software was used for ROC analysis of
each FMIA to determine an optimized cutoff that maximizes both
the diagnostic specificity and diagnostic sensitivity of each assay.
Oral fluid samples from a known positive population (20 samples
from type I PRRSV-infected animals and 83 samples from type II
PRRSV-infected animals) and oral fluid samples from a known
negative population (385 samples from PRRSV-free animals)
were analyzed. For comparison, serum samples from a known
positive population (176 samples from type I PRRSV-infected an-
imals and 716 samples from type II PRRSV-infected animals) and
serum samples from a known negative population (368 samples
from PRRSV-free animals) were analyzed. These samples were
obtained from experimental animals as described inMaterials and
Methods (sample sets A to D). The optimal cutoff value and diag-
nostic sensitivity and specificity of each individual test are pre-
sented in Fig. 4. Each oral fluid-based FMIA showed90% diag-
nostic sensitivity and specificity (Fig. 4A), while95% diagnostic
sensitivity and specificity were achieved for serum-based FMIAs
(Fig. 4B). Table 1 summarizes the results of ROC analysis. Diag-
nostic sensitivity and specificity were generally lower for the oral
fluid-based assays. This result was expected since the antibody
concentration in serum is substantially higher than that in oral
fluid (refer to Fig. 6 and the detailed description below).
(iv) Assessment of test repeatability. The precision of each
individual FMIA was determined using internal control stan-
dards. Table 2 shows the intra-assay and interassay repeatability of
each test. Both intra-assay and interassay repeatability values were
10%CV for all tests, which suggests that these FMIAs are highly
repeatable in diagnostic applications.
(v)Development of amultiplex assay.Oncewe validated each
individual nsp7- and N-based FMIA in singleplex format, we
combined the singleplex assays into a 4-plex assay. The 4-plex
assay was compared with the singleplex assays to determine
whether there was any cross-reactivity among bead sets. Each oral
fluid and serum internal control standard along with the individ-
ual corresponding bead set was first tested in a singleplex format
and then combined for testing in a 4-plex format. Correlation
coefficients were determined for comparison between each indi-
vidual N- and nsp7-based FMIA and the 4-plex assay. As shown in
Fig. 5, there was no statistical difference between multiplex and
singleplex analytes at any time point for both oral fluid (Fig. 5A)-
and serum (Fig. 5B)-based assays. Both nsp7- andN-based FMIAs
demonstrated high correlation coefficients (0.98), indicating
that there is very little cross-reactivity with the presence of multi-
ple protein-coupled microspheres.
Evaluation of swine antibody response in oral fluid and se-
rum samples. Once we validated the FMIA, we further tested the
TABLE 1 Summary of ROC analysis of oral fluid- and
serum-based FMIAs
Test and parameter
Value
NA nsp7 EU nsp7 NA N EU N
Serum FMIA n 1,084 n 555 n 1,084 n 555
Sensitivity 98.2 99.4 99.3 100
Specificity 95.1 96.3 98.9 99.7
Oral fluid FMIA n 374 n 114 n 374 n 114
Sensitivity 92.8 95.0 100 95.0
Specificity 93.1 91.5 97.5 95.7
TABLE 2 Assay repeatability of oral fluid- and serum-based FMIAs
Repeatability assay
%CV
nsp7-based
assays
N-based
assays
NA EU NA EU
Serum intra-assay repeatability 1.0 2.3 1.9 1.7
Serum interassay repeatability 3.2 4.2 4.7 3.4
Oral fluid intra-assay repeatability 5.8 6.9 3.2 1.5
Oral fluid interassay repeatability 7.8 9.1 3.0 1.4
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feasibility of applying this test in an experimental study. Initially,
we compared the amounts of antibody present in oral fluid and
serum. We used paired oral fluid and serum samples that were
collected at 21 dpi from the same individual pigs (sample set A).
The relative anti-N and anti-nsp7 antibody concentrations were
determined. As shown in Fig. 6, the EUandNAnsp7-based FMIAs
showed 4.0 times and 8.4 times greater concentrations of detect-
able nsp7 antibody, respectively, in serum than in oral fluid. Both
EU and NA N protein-based FMIAs showed a 2.6-fold difference
in the level of anti-N antibody between serum and oral fluid.
The FMIA was further employed to investigate the kinetics of
the antibody responses in oral fluid and serum samples. Initially, a
panel of oral fluid samples (sample set E) from 1,100 type II
PRRSV-infected pigs collected at 7-day intervals was evaluated by
NA nsp7- and NAN-based FMIAs. As shown in Fig. 7A, antibody
responses to nsp7 and N could be detected as early as 14 dpi and
FIG 5 Development of 4-plex fluorescent microsphere immunoassay. Each individual corresponding bead set (indicated in each panel) was first tested in
singleplex format and then combined for testing in 4-plex format. (A) Oral fluid-based FMIAs; (B) serum-based FMIAs. The correlation coefficient (R2)
indicated in each panel was determined for comparison between each singleplex assay and the 4-plex FMIA.
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lasted until 56 dpi (end of the study). The NA N-based FMIA was
more sensitive for the detection of early infection (14 and 21 dpi),
but theNAnsp7-based FMIA detected a higher antibody response
after 28 days postinfection. We further evaluated the kinetics of
the antibody response in serum samples (Fig. 7B). Serum samples
from serial bleeds (sample set C; n  1,014) were obtained from
109 pigs experimentally infected with type II PRRSV. Serum sam-
ples were collected at 7-day intervals for the first 2 weeks and then
at 14-day intervals for up to 202 days postinoculation. There were
similar peak antibody responses detected by both NA nsp7- and
NA N-based FMIAs. Interestingly, seroconversion could be de-
tected as early as 7 dpi in both FMIAs, while it would normally be
detected at 14 dpi by ELISAs (1), suggesting the earlier appearance
of FMIA-detectable antibody than ELISA-detectable antibody.
Applicationof 4-plexFMIA fordetectionofPRRSV infection
in field samples. The robustness of the FMIA was further evalu-
ated with field samples. Since there are no oral fluid samples avail-
able for routine serological diagnosis in diagnostic laboratories,
field serum samples were used to assess the efficacy of the FMIA.
Each sample was tested simultaneously for its reactivity with the
EU-nsp7, NA-nsp7, EU-N, and NA-N antigens by using the
4-plex assay. A total of 772 field serum samples (sample set F)
submitted to the South Dakota Animal Disease Diagnostic Labo-
ratory were evaluated. These samples were initially tested by
IDEXX ELISA and then tested by 4-plex FMIA. Comparing FMIA
with IDEXX ELISA, 383/383 (100%) IDEXX ELISA-positive sam-
ples tested positive by the nsp7- and N-based 4-plex FMIA. Sim-
ilarly, of the field samples originally testing negative by IDEXX
ELISA, 384/389 (98.7%) were negative by the nsp7-based FMIA,
while 389/389 (100%) tested negative by the N protein-based
FMIA (Table 3).
DISCUSSION
The development of diagnostic tests that are able to detect
PRRSV-specific antibodies in oral fluid samples offers an impor-
tant tool for PRRS surveillance in commercial herds and boar
studs. Oral fluid sampling has marked advantages over serum
sampling, including lower labor/material costs, noninvasive col-
lection, and lower biosecurity risks because samples can be col-
lected by site personnel. This is more important for PRRS surveil-
lance programs at the population level. The development of oral
fluid-based diagnostic tests will be a significant breakthrough in
our effort to control PRRSV, because it will be a major improve-
ment in our ability to cheaply and efficiently track PRRSV infec-
tions in both populations and individual animals. A previous
study of 10 wean-to-finish commercial barns showed that oral
fluid sampling of 6 of 42 pens (1,100 head) at 2-week intervals
effectively and efficiently detected circulation of PRRSV, porcine
circovirus type 2 (PCV2), and swine influenza virus (SIV) by PCR
(11, 12). In this study, we developed a multiplex FMIA using oral
fluid. For comparison, a serum-based FMIA was also developed.
FIG 6 Comparison of the amounts of antibody present in oral fluid and
serum. Paired oral fluid and serum samples were collected at 21 dpi from the
same individual pigs (n 21), and the anti-N and anti-nsp7 antibody concen-
trations were determined by 4-plex FMIA.
FIG 7 Kinetics of antibody responses in serum and oral fluid samples. (A) A panel of pooled oral fluid samples (n 9) from 1,100 type II PRRSV-infected pigs
collected at 7-day intervals was evaluated by FMIA. (B) A total of 1,014 serum samples obtained from 109 pigs experimentally infected with type II PRRSV were
tested by FMIA. The samples were collected at 7-day intervals for the first 2 weeks and then at 14-day intervals for up to 202 dpi. The S/P ratio was calculated as
follows: S/P (MFI of sampleMFI of buffer)/(MFI of positive controlMFI of buffer).
TABLE 3 Comparison of FMIA with IDEXX ELISA for evaluation of
field serum samples
Serum group
No. of samples
IDEXX
positive
IDEXX
negative
FMIA
positive
FMIA
negative
IDEXX-positive population
(n 383)
383 0 383 0
IDEXX-negative
population (n 389)
0 389 5 384
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These assays are based on the detection of antibodies against the
nsp7 and N proteins of both genotypes of PRRSV. N protein was
selected as an antigen because it is highly conserved among differ-
ent strains of PRRSV and because all current commercially avail-
able serological tests are based on this protein. nsp7 was selected
based on the highly immunogenic nature of the protein (1). Both
antigens were prepared by expression as recombinant proteins in
E. coli. It was noted that generation of highly purified recombinant
proteins and maintenance of the native conformation of proteins
were required for the test. High-level expression of N protein re-
sulted in the formation of inclusion bodies, requiring a refolding
step to restore the native conformation of the protein. nsp7 was
expressed as a soluble recombinant protein in bacterial culture,
which is convenient for antigen preparation, especially applied to
diagnostic settings requiring large volumes of antigen. However,
the protein seems sensitive to degradation. It is important to en-
sure that the recombinant protein is handled properly, such as by
preventing multiple freeze-thaw cycles, keeping the protein at
cold temperatures, and including protease inhibitors in the re-
combinant protein extraction and purification reagents.
The FMIAs using type I PRRSV antigens seemed to have
slightly lower diagnostic sensitivity and specificity than those of
the assays using type II PRRSV antigens. This could have been
caused by the small sample size of oral fluid from type I PRRSV-
infected pigs, which may bias the statistical analysis. Since pen-
based sampling was used for oral fluid, it reduced the actual num-
ber of samples. The panel of type I PRRSV oral fluid samples used
in this study was generated from a recent pig study at South Da-
kota State University. Unfortunately, this type of sample is not
available for antibody detection in other diagnostic or research
laboratories in theUnited States. In addition, since oral fluid is not
a routine sample for antibody evaluation in diagnostic laborato-
ries, wewere unable to test the feasibility of applying FMIA to field
oral fluid samples. Instead, serum samples were used for further
validation of the FMIA in field settings. We expect that our initial
studies with oral fluid, including the current FMIA development
study, will change traditional serum-based sampling methods,
and oral fluidmay eventually become a standard sample routinely
used for diagnostic evaluation.
In comparing the oral fluid-based assay to the serum-based
assay, the oral fluid-based assay had a slightly lower diagnostic
sensitivity and specificity. This result was expected, since we have
shown that lower concentrations of antibodies are present in oral
fluid samples. The markedly lower levels of antibody in oral fluid
may be due to physiological and anatomical differences in how
antibody is secreted through gingival crevicular tissues. On the
other hand, theymay be due to environmental factors such as high
levels of proteases present in the buccal mucosa and oral fluid. In
comparison to oral fluid-based ELISA, the oral fluid-based FMIA
had a significantly higher signal-to-noise ratio (9.9 and 2.4 for N
protein-based FMIA and ELISA, respectively). Although further
optimization of oral fluid-based ELISA may be necessary to im-
prove the test sensitivity, our results demonstrate the feasibility of
using FMIA as an alternative to ELISA for serological detection of
PRRSV infection in oral fluid.
The FMIA we developed with the PRRSV nsp7 and N antigens
provided important information regarding the kinetics of the an-
tibody response of pigs to these proteins during the time course of
infection. In comparison to the antibody responses to different
antigens, a higher level of antibody response to N protein was
observed in early infection (14 dpi), but the antibody titer to nsp7
was higher after 28 dpi and remained at a high level through the
end of the experiment (56 dpi). Another interesting observation is
that the antibody response could be detected as early as 7 dpi by
FMIA with serum samples. In our previous study, the same panel
of serum samples was tested by IDEXX ELISA and nsp7 ELISA.
The earliest detection of an antibody response was at 14 dpi (1).
These results demonstrate a greater analytical sensitivity of FMIA
than ELISA. In serum FMIA, antibody detection seemed to reach
the maximal level after 28 dpi. There were similar peak antibody
titers to nsp7 and N proteins, and the antibody responses to both
proteins were sustained through 202 days postinfection. These
results will be important for future applications of FMIA in PRRS
surveillance programs. Data on the proportion of a herd popula-
tion that is immune or has been infected have many important
epidemiologic applications for disease control, including (i) de-
termining the timing of infection and/or immune status, (ii) iden-
tifying susceptible groups in the population so that such animals
can be quarantined or removed in a timely fashion to prevent
transmission to naïve animals, and (iii) using these data in math-
ematical modeling to predict disease outbreaks and design better
management strategies.
In summary, we have developed an FMIA that is able to detect
virus-specific antibodies in oral fluid. This study represents the
“proof-of-concept” phase for new PRRS diagnostic test develop-
ment using oral fluid samples. The availability of the oral fluid-
based assay will translate into an improvement in our ability to
conduct field studies and monitor herd health status in regional
control programs. This technology can be applied to other swine
pathogens, including PCV2, SIV, and Mycoplasma hyopneu-
moniae, and this is currently under development in our laborato-
ries. Our ultimate goal is to develop rapidmultiplex tests to detect
various swine pathogens simultaneously in a single test sample.
We believe that success in this will revolutionize thewaywe survey
diseases in swine herds by using a more efficient method as we
move toward control and elimination of specific diseases.
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